Press release
Neuroendocrine Carcinoma Therapeutics Market - Epidemiology Analysis, Development, Growth and Demand Forecast to 2023
Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.Explore Report at: www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market
The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some major companies that are determined to develop therapeutics for various neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline candidates that are presently being studied for their therapeutic efficacy in the treatment of neuroendocrine cancer. Also, there are many other pipeline drugs in Phase III which are expected to enter the neuroendocrine carcinoma therapeutics market in the future.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market/toc-sample
Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Callisto Pharmaceuticals Pvt. Ltd., Biosynthema, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com
347, 5th Ave. #1402
New York City, NY - 10016
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroendocrine Carcinoma Therapeutics Market - Epidemiology Analysis, Development, Growth and Demand Forecast to 2023 here
News-ID: 493256 • Views: …
More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…

Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…

Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Neuroendocrine
Neuroendocrine Carcinoma Market Massive Growth opportunity Ahead
Introduction
Neuroendocrine carcinoma (NEC) is a rare and aggressive form of cancer that arises from neuroendocrine cells, which are found throughout the body and are responsible for producing hormones. These tumors can occur in various organs, including the lungs, pancreas, liver, and gastrointestinal tract. Due to its often vague and non-specific symptoms, neuroendocrine carcinoma is frequently diagnosed at an advanced stage, making it challenging to treat effectively.
In recent years, however, there…
Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR)…
Emerging Trends Influencing The Growth Of The Neuroendocrine Tumor Treatment Mar …
The Neuroendocrine Tumor Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Be by 2034?
The market for neuroendocrine tumor treatment has seen a significant expansion in recent years. Projected to grow from a value…
Prominent Neuroendocrine Tumor Treatment Market Trend for 2025: Clinical Trials …
How Are the key drivers contributing to the expansion of the neuroendocrine tumor treatment market?
The neuroendocrine tumor treatment market is forecasted to expand due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, or NETs, are rare growths that begin in neuroendocrine cells, and their treatment is vital to managing the symptoms, controlling the tumor's growth, and applying radiation therapy to destroy the cancerous cells. The American Society of Clinical…
Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise…
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.
Neuroendocrine Cancer Market Segmentation Analysis
Total Neuroendocrine Cancer Studies: 2499
By Drug Type
Everolimus
Sunitinib Malate
Lanreotide
Octreotide
Others
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of…